Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	OSPREY MEDICAL INC.	
ARBN	152 854 923	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael McCormick
Date of last notice	15 May 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A	
Date of change	24 May 2019 (US time)	
No. of securities held prior change	980,392	Options with exercise price of US\$0.25 per Share
	1,180,000	Options with exercise price of US\$0.80 per Share
	100,000	Options with exercise price of US\$0.84 per Share
	500,000	Options with exercise price of A\$1.31 per Share
	250,000	Options with exercise price of A\$1.16 per Share
	1,510,000	Options with exercise price of A\$0.82 per Share

⁺ See chapter 19 for defined terms.

	705 000	0
	725,000	Options with exercise price of A\$0.38 per Share
	2,370,000	Options with exercise price of A\$0.26 per Share
	Total: 7 <u>.615,3</u> equival	92 Options (exercisable into an ent of 15,230,784 CDIs)
	16,000 CDIs (8,00	00 in equivalent Shares)
Class	Options over Shar	res (not quoted)
Number cancelled	3,540,000 Options (exercisable into an equivalent of 7,080,000 CDIs) pursuant to the terms of a stock option exchange program (Option Exchange) approved by stockholders on 9 May 2019.	
Number granted	3,540,000 Options (exercisable into an equivalent of 7,080,000 CDIs) pursuant to the terms of the Option Exchange and a grant of Options approved by stockholders on 9 May 2019.	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil	
No. of securities held after change	980,392	Options with exercise price of US\$0.25 per Share
	725,000	Options with exercise price of A\$0.38 per Share
	2,370,000	Options with exercise price of A\$0.26 per Share
	3,540,000	Options with exercise price of A\$0.23 per Share
	Total: 7,615,392 Options (exercisable into an equivalent of 15,230,784 CDIs) (No change to total number of Options held)	
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	3,540,000 Options were issued to Michael McCormick following the surrender and cancellation of 3,540,000 Options pursuant to the terms of the Option Exchange and grant of Options approved by stockholders on 9 May 2019.	

Appendix 3Y Page 2 01/01/2011

⁺ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 - +Closed period

Were the interests in the securities or contracts detailed above	No
traded during a *closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.